Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will present six abstracts at ASCO-GU Feb 26-28, 2026 reporting clinical performance for Precise MRD, Prolaris, and MyRisk oncology tests. Key data include ultra-sensitive ctDNA detection (below 100 ppm), a meta-analysis of 14 studies >8,000 patients showing Prolaris prognostic power, and germline testing results across Gleason and NCCN risk groups.

Findings are largely interim or preliminary but indicate potential diagnostic and prognostic value across genitourinary cancers.

Positive

• Prolaris meta-analysis covers 14 studies >8,000 patients
• Precise MRD detects ctDNA in the ultrasensitive range <100 ppm
• Prolaris prognostic for distant metastasis and prostate-cancer mortality

Negative

• Most results are interim or from maturing trials, limiting clinical certainty
• Early evidence shows correspondence between ctDNA and outcomes but is not definitive

News Market Reaction – MYGN

+1.14%

13 alerts

+1.14% News Effect

+9.8% Peak in 50 min

+$5M Valuation Impact

$408M Market Cap

3K Volume

On the day this news was published, MYGN gained 1.14%, reflecting a mild positive market reaction. Argus tracked a peak move of +9.8% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $408M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Studies in meta-analysis: 14 studies Patients in meta-analysis: more than 8,000 patients ctDNA detection level: below 100 parts per million +5 more

8 metrics

Studies in meta-analysis 14 studies Prolaris prostate cancer prognostic meta-analysis

Patients in meta-analysis more than 8,000 patients Prolaris prognostic power assessment

ctDNA detection level below 100 parts per million Precise MRD ultrasensitive detection in genitourinary cancers

Conference dates Feb. 26–28 ASCO Genitourinary Cancers Symposium timing

Booth number booth #20 Myriad exhibition location at ASCO-GU

Poster board J16 Poster Board Number: J16 Precise MRD urothelial cancer poster

Prolaris poster M22 Poster Board Number: M22 Prolaris biopsy meta-analysis presentation

MyRisk poster K14 Poster Board Number: K14 MyRisk germline testing in localized prostate cancer

Market Reality Check

Price: $4.43 Vol: Volume 1,543,022 is above...

high vol

$4.43 Last Close

Volume Volume 1,543,022 is above the 20-day average of 1,017,777, indicating elevated interest ahead of ASCO-GU data. high

Technical Shares at $4.38 are trading below the 200-day MA ($6.05), reflecting a longer-term downtrend despite recent strength.

Peers on Argus

MYGN is up 2.1% on strong ASCO-GU clinical data while scanner activity shows pee...

1 Down

MYGN is up 2.1% on strong ASCO-GU clinical data while scanner activity shows peer CDNA down 2.61% with no news, pointing to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Earnings and guidance	Positive	+2.1%	Reported Q4 and 2025 results and reiterated 2026 revenue and EBITDA guidance.
Feb 19	Clinical validation news	Positive	-0.3%	Published analytical validation for FirstGene prenatal screen with high sensitivity and specificity.
Feb 16	Earnings date notice	Neutral	+0.2%	Announced timing and webcast details for upcoming Q4 and full-year 2025 results.
Jan 27	MRD commercialization plan	Positive	+1.9%	Outlined March 2026 limited launch of Precise MRD backed by strong ctDNA sensitivity data.
Jan 12	Prelim results, guidance	Positive	-0.1%	Released preliminary Q4/2025 revenue ranges and introduced 2026 revenue and EBITDA guidance.

Pattern Detected

Recent fundamentally positive updates (earnings, MRD data, product validation) have more often seen modestly positive price alignment, but there are instances where favorable clinical or guidance news was followed by flat-to-negative reactions.

Recent Company History

Over the past several weeks, Myriad reported Q4 2025 results with $209.8M revenue and reiterated 2026 guidance, highlighted new data and commercialization steps for Precise MRD, and published validation for the FirstGene prenatal screen. Preliminary 2025 trends and 2026 guidance were first outlined in January. Today’s ASCO-GU abstracts extend the same oncology testing narrative, reinforcing earlier MRD performance data and underscoring the role of Prolaris and MyRisk within prostate and genitourinary cancer care.

Market Pulse Summary

This announcement underscores Myriad’s focus on oncology diagnostics, highlighting Precise MRD, Prol...

Analysis

This announcement underscores Myriad’s focus on oncology diagnostics, highlighting Precise MRD, Prolaris, and MyRisk across bladder, urothelial, renal, and prostate cancers. Meta-analysis data spanning 14 studies and over 8,000 patients and ultrasensitive ctDNA detection below 100 parts per million reinforce test performance claims. Investors may track future updates on clinical outcomes correlations, guideline or payer adoption, and how these platforms contribute to the reiterated 2026 growth and profitability framework outlined in recent earnings disclosures.

Key Terms

molecular residual disease, ctdna, meta-analysis, prognostic, +4 more

8 terms

molecular residual disease medical

"including ultra-sensitive molecular residual disease detection, prognostic stratification,"

Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.

ctdna medical

"with many detection events at ctDNA concentrations in the ultrasensitive range"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

meta-analysis technical

"results of a robust meta-analysis of 14 studies involving more than 8,000 patients"

A meta-analysis combines results from multiple independent studies on the same question to produce a single, more reliable estimate of an effect or outcome. Like averaging many temperature readings to get a truer picture of the weather, it reduces random noise and highlights consistent signals; investors use it to assess how strong and reliable the scientific or economic evidence is, which affects regulatory outlook, product prospects, and valuation risk.

prognostic medical

"We demonstrate with deep statistical rigor that Prolaris is highly prognostic and additive"

Prognostic describes something that gives information about the likely future course or outcome of a condition, such as how severe a disease will become or how long it might last. For investors, prognostic markers, tests, or statements matter because they can change expectations about a drug’s market need, trial design, regulatory path, or long-term revenue—like a weather forecast that helps decide whether to carry an umbrella or change plans.

germline medical

"comparable likelihood to identify a germline variant across risk groups, which may help"

Germline describes genetic changes that occur in reproductive cells (sperm or eggs) and therefore can be passed to future generations. Think of it as an inherited blueprint update rather than a one‑off repair in a single person; that permanence raises different scientific, ethical and regulatory questions. For investors, germline work matters because it affects long‑term safety concerns, approval pathways, public acceptance and potential market size for genetic therapies.

gleason score medical

"association with Gleason score and NCCN risk grouping."

A Gleason score is a number assigned by a pathologist after examining prostate tissue under a microscope to describe how much the cancer cells differ from normal cells and how likely the tumor is to grow and spread. Think of it as a heat‑map rating for aggressiveness: higher scores mean more aggressive disease and a greater need for intensive treatment. For investors, Gleason scores influence expected patient outcomes, treatment choices, and the market size and urgency for related diagnostics and therapies.

nccn risk grouping medical

"association with Gleason score and NCCN risk grouping."

NCCN risk grouping is a standardized system developed by the National Comprehensive Cancer Network that sorts cancer patients into low-, intermediate- or high-risk categories based on clinical features and test results. Investors should care because these risk bands shape which patients get which treatments, influence clinical trial design and approval pathways, and help estimate a drug’s addressable market and likely reimbursement—much like rating neighborhoods to predict demand for a new store.

whole-genome sequencing medical

"ultra-sensitive molecular residual disease detection via tumor-informed whole-genome sequencing-based"

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its Precise MRD^TM (Molecular Residual Disease) Test, Prolaris^® Prostate Cancer Prognostic Test and MyRisk^® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification, and inherited cancer risk assessment.

“The data Myriad is presenting at ASCO-GU suggest our oncology products go further than standard approaches to deliver unique insights for patients with cancer,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Our MRD test may reveal clinically consequential information that may not have been attainable on first-generation tests. We demonstrate with deep statistical rigor that Prolaris is highly prognostic and additive to classical risk categories. Finally, we find that MyRisk has comparable likelihood to identify a germline variant across risk groups, which may help to broaden the scope of those who receive and benefit from testing.”

Multiple studies presented at ASCO-GU will highlight the performance of Precise MRD in genitourinary cancers, including bladder cancer, urothelial cancer, and renal cell carcinoma. In these analyses, sensitivity was high at the baseline time point, with many detection events at ctDNA concentrations in the ultrasensitive range below 100 parts per million. Though the trials are still maturing, the early evidence to be presented at ASCO-GU suggests a correspondence between ctDNA levels and clinical outcomes.

The company will share results of a robust meta-analysis of 14 studies involving more than 8,000 patients that support the prognostic power of the Prolaris Prostate Cancer Prognostic Test. The meta-analysis indicates that Prolaris is significantly prognostic for both distant metastasis and prostate-cancer specific mortality. These data help explain why Prolaris is uniquely suited to help guide initial treatment decisions. Importantly, Prolaris was found to be significantly prognostic above and beyond conventional risk categories driven by clinical factors alone.

Finally, data will be presented evaluating germline testing using the MyRisk Hereditary Cancer Test in localized prostate cancer, including the prevalence of pathogenic variants and their association with Gleason score and NCCN risk grouping. The data indicate that germline positivity rates do not significantly differ across the Gleason-score groups or NCCN risk groups, suggesting that it may not be appropriate to limit germline testing only to those with high Gleason or NCCN risk.

These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, San Francisco, Calif., Myriad will exhibit at booth #20. For more information, visit: https://myriad.com/oncology/conferences/

Myriad Genetics Presentations
Precise MRD
Ultra-sensitive molecular residual disease detection via tumor-informed whole-genome sequencing-based ctDNA assay in resectable urothelial cancer in the MONSTAR-SCREEN-3 project
Poster Board Number: J16; Abstract Number: 810
Friday, Feb. 27 11:30 AM - 12:45 PM PST, 4:45 PM - 5:45 PM PST
Presenter: Shigehiro Tsukahara, Kyushu University, Fukuoka, Japan

CONSOLIDATE: Interim Results from a Phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA
Poster Board Number: N25; Abstract Number: TPS912
Friday, Feb. 27 11:30 AM - 12:45 PM PST; 4:45 PM - 5:45 PM PST
Presenter: Patrick Carriere, MD, MD Anderson Cancer Center

Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model
Rapid Oral Abstract; Abstract Number: 537
Saturday, Feb. 28, 12:45 PM - 1:30 PM PST
Presenter: Chad Tang, MD, The University of Texas MD Anderson Cancer Center

Ultra-sensitive whole-genome sequencing-based molecular residual disease detection in resectable renal cell carcinoma: Preliminary results from the MONSTAR-SCREEN-3 study
Rapid Oral Abstract; Abstract Number: 421
Saturday, Feb. 28, 12:45 PM - 1:30 PM PST
Presenter: Taigo Kato, MD, PhD, Osaka University, Osaka, Japan

Prolaris Prostate Cancer Prognostic Test
The Prolaris Test on diagnostic biopsy for localized prostate cancer prognosis across risk groups and management: An individual participant data meta-analysis
Poster Board Number: M22; Abstract Number: 394
Thursday, Feb. 26, 11:30 AM - 12:45 PM PST and 5:45 PM - 6:45 PM PST
Presenter: Steven Monda, MD, University of Michigan

MyRisk Hereditary Cancer Test
Rethinking germline testing in localized prostate cancer: Prevalence of germline variants and association with Gleason score and NCCN risk grouping
Poster Board Number: K14; Abstract Number: 322
Thursday, Feb. 26, 11:30 AM - 12:45 PM PST and 5:45 PM - 6:45 PM PST
Presenter: Adam Cole, MD, TruCore Pathology

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Myriad Genetics tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.

Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the company’s intent to present new data at the 2026 ASCO-GU conference regarding its Precise MRD, Prolaris and MyRisk tests, and that these data are expected to highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification, and inherited cancer risk assessment. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com  

FAQ

What did Myriad (MYGN) present about Precise MRD at ASCO-GU Feb 26-28, 2026?

Precise MRD showed ultra-sensitive ctDNA detection, often below 100 parts per million. According to the company, baseline sensitivity was high with many detection events at ultrasensitive ctDNA concentrations, mainly in genitourinary cancers including bladder and renal cell carcinoma.

How significant is the Prolaris meta-analysis Myriad (MYGN) presented at ASCO-GU 2026?

The Prolaris meta-analysis pooled 14 studies covering over 8,000 patients and found significant prognostic power. According to the company, Prolaris predicts distant metastasis and prostate-cancer specific mortality beyond conventional clinical risk categories.

What did Myriad (MYGN) report about MyRisk germline testing in localized prostate cancer?

MyRisk positivity rates did not significantly differ across Gleason scores or NCCN risk groups. According to the company, this suggests limiting germline testing to only high-risk groups may miss pathogenic variants across risk strata.

Do Myriad’s ASCO-GU 2026 findings for Precise MRD prove clinical outcome benefit now?

No; findings are early and primarily interim, so definitive outcome benefits are not yet proven. According to the company, trials are still maturing though early evidence suggests correspondence between ctDNA levels and clinical outcomes.

Which Myriad (MYGN) presentations should investors note at ASCO-GU Feb 26-28, 2026?

Investors should note six abstracts: Precise MRD studies in urothelial and renal cancers, a Prolaris meta-analysis, and a MyRisk prostate study. According to the company, posters and rapid oral abstracts summarize these key oncology data presentations.

How might the ASCO-GU 2026 data affect Myriad (MYGN) commercially in 2026–2027?

Data could support broader clinical adoption if validated, but timelines remain uncertain due to interim status. According to the company, results are promising for diagnostic and prognostic roles but require further maturation and validation before changing standard practice.